Emmanuel Normant - Concepedia

Author

Emmanuel Normant

Infinity Pharmaceuticals (United States)ORCID

Also Known As

E Normant, E. Normant, Emmanuel Normant, Emmanuel Y. Normant, Rachel W. O’Connor

138

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Infinity Pharmaceuticals (United States)Constellation Pharmaceuticals (United States)National Institutes of Health Dana-Farber Cancer Institute Harvard University

About

Emmanuel Normant is an author at Infinity Pharmaceuticals (United States) specializing in medicine, pharmacology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	2.1K
2	Cell Biology	6	6	755
3	Natural Sciences	5	5	588
4	Biochemistry	4	4	374
5	Health Sciences	1	1	52

Emmanuel Normant

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Carboxypeptidase E Is a Regulated Secretory Pathway Sorting Receptor: Genetic Obliteration Leads to Endocrine Disorders in Cpefat Mice David R. Cool, Emmanuel Normant, Fusheng Shen, Cell Cpefat MiceMolecular PhysiologySignal TransductionEndocrine MechanismG Protein-coupled Receptor	1997	454
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors Thomas De Raedt, Zandra E. Walton, Jessica L. Yecies, Cancer Cell Tumor BiologyCancer Cell VulnerabilitiesMedicineImmune Checkpoint InhibitorCancer Biology	2011	257
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 Jens Sydor, Emmanuel Normant, Christine Pien, Proceedings of the National Academy of Sciences Tumor BiologyMedicinal ChemistryMedicineMyeloma Cell LinesHsp90 Inhibitor	2006	226
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials Brian K. Albrecht, Victor Gehling, Michael C. Hewitt, Journal of Medicinal Chemistry ImmunologyPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2016	214
Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas Rishi G. Vaswani, Victor Gehling, Les A. Dakin, Journal of Medicinal Chemistry	2016	214
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors Michele Ceribelli, Priscilla N. Kelly, Arthur L. Shaffer, Proceedings of the National Academy of Sciences	2014	191
Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90 Jie Ge, Emmanuel Normant, James R. Porter, Journal of Medicinal Chemistry Hydroquinone DerivativesMedicinal ChemistryWater-soluble InhibitorsBiochemistryMedicine	2006	189
EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation William D. Bradley, Shilpi Arora, Jennifer Busby, Chemistry & Biology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyCancer Cell Biology	2014	148
The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models Emmanuel Normant, Guillermo Paez, Kip A. West, Oncogene OncologyEml4–alk LevelsAlk-driven Nsclc ModelsMedicineHsp90 Inhibitor Ipi-504	2011	144
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 Gaël Roué, Patricia Pérez‐Galán, Mònica López‐Guerra, Blood	2010	108

Page 1